On April 21, Bairen Medical (688198) recently released its 2020 annual report, and the company achieved operating income of 181,917,903.34 yuan during the reporting period, an increase of 24.57% year-on-year; the net profit attributable to shareholders of listed companies was 56,525,365.98 yuan, down 10.40% year-on-year.
Net cash flow from operating activities during the reporting period was RMB50,764,073.77, and net assets attributable to shareholders of the listed company as of the end of 2020 were RMB837,197,093.66.
In 2020, the company overcame the impact of the epidemic, worked hard to open up the market, adjusted the marketing strategy, and the operating income increased by 24.57% over the same period of the previous year.
During the reporting period, the main reason for the decline in the company's profit was the recognition of share payment expenses of 34.1954 million yuan in the second half of the year; at the same time, the company's increased R&D investment and marketing efforts also led to larger R&D expenses and sales expenses, which made the income-related indicators decline year-on-year: net profit attributable to shareholders of listed companies fell by 10.40% year-on-year, net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses fell by 30.30% year-on-year, and basic earnings per share fell by 32.95% year-on-year. Basic earnings per share, net of non-recurring gains and losses, decreased by 47.56% year-on-year.
Excluding the impact of share payments, the company's net profit attributable to shareholders of listed companies and net profit attributable to shareholders of listed companies during the reporting period before non-recurring gains and losses were 87.348 million yuan and 71.8615 million yuan, an increase of 38.46% and 22.06% year-on-year, basic earnings per share of 0.91 yuan per share, an increase of 3.41% year-on-year, and basic earnings per share after deducting non-recurring gains and losses of 0.75 yuan per share, down 8.54% year-on-year. The Company's issuance of ordinary shares in December 2019 resulted in an increase in the number of shares and a decrease in earnings per share.
According to the announcement, the total remuneration of directors, supervisors and senior management during the reporting period was 5.941 million yuan. The total pre-tax remuneration received by Chairman, General Manager and Core Technician Jin Lei from the company was 744,600 yuan, and the total pre-tax remuneration received by Director, Deputy General Manager and Core Technical Personnel Li Liyan from the company was 489,600 yuan.
According to the data of the digging shell network, Bairen Medical is a leading domestic technology research and development platform enterprise for animal-derived implant-interventional medical devices, covering three major areas: heart valve replacement and repair, congenital heart disease implant interventional treatment and surgical soft tissue repair.
This article originated from the digging shell network
![Scarce large flats in the middle of the city! This is the real trump card of Jin Lei Phoenix[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)